Actavis Group, the international generic pharmaceuticals company, today announced the launch of Lercanidipine in five European countries. Lercanidipine is mainly used to treat high blood pressure.
Actavis launched the product under its own brand name on day one in the UK and France, where the patents expired on 20 and 21 January, respectively. The product was also launched on day one in France, the UK, the Netherlands, Belgium and Italy by clients of Medis, Actavis’ Third-party sales division.
Lercanidipine Actavis will be launched in various other European countries as patents expire in the near future.
Lercanidipine tablets, indicated for hypertension, are the generic equivalent of Zanidip and Lercadip. Lercanidipine from Actavis is available in 10mg and 20mg tablets.
Brand sales in the EU were EUR290m in the 12 month period ended September 2009, with France and the UK accounting for EUR130m of the sales over the same period (IMS Health data).
Generic Lercanidipine was developed by Actavis in Iceland and is manufactured by Actavis in Malta.